WELL Health Technologies Corp T.WELL

Alternate Symbol(s): WHTCF | T.WELL.DB

Healthcare Medical Care

WELL Health Technologies Corp. is a Canada-based practitioner-focused digital healthcare company. Its healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. Its business units include Canadian Patient Services, WELL Health USA Patient and Provider Services, and SaaS and Technology Services. Its solutions enable more than 38,000 healthcare providers between the United States and Canada and power owned and operated healthcare ecosystem in Canada with over 200 clinics supporting primary care, specialized care, and diagnostic services. In the United States its solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL Health USA Patient and Provider Services consists of four assets: CRH Medical, Provider Staffing, Circle Medical and Wisp. It provides cybersecurity protection and patient data privacy solutions.

TSX:WELL - Post by User

WELL Health Technologies Corp > Scotia Analysis - STRONG START TO 23 -OR LISTEN TO BUTTCOCKS

<< Previous

Bullboard Posts

Next >>

Post by SunsetGrillon May 15, 2023 9:18am

353 Views

Post# 35447987

Scotia Analysis - STRONG START TO 23 -OR LISTEN TO BUTTCOCKS

OUR TAKE: Positive. WELL delivered a strong start to 2023 with a beat across the board, while it’s seeing minimal impacts due to inflationary, recessionary, and supply chain pressures facing many other companies given the diversity and resiliency of its model (95% revenue recurring/re-occurring). We see compelling value at current levels with the stock trading at 12.7x C2024 EBITDA. Multiple upside opportunities exist to WELL’s updated 2023 guidance including better organic growth trends and M&A. Maintain Sector Outperform.

KEY POINTS

Q1 beats across the board on strong organic growth trends. Revenue was up 21% y/y on an organic basis, with strength in both the U.S. (Circle Medical +93% y/y and WISP +56% y/y for +42% of US mix) and in Canada (Canadian Patient Services including MyHealth + Clinics +18% y/y organically). In Canada, Clinics benefited from a one-time stabilization payment from the BC government (~$0.5M) in addition to higher billings from the newly implemented payment model for BC doctors (starting in Feb). MyHealth was helped by the addition of new cardiologists and also saw a higher level of billable hours for diagnostic procedures (2022 was impacted by staff shortages). In the US, CRH Medical was up 10% qoq vs historical seasonal declines, as the unit benefited from a promotional campaign for its O’Regan product (related sales were 40% y/y and q/q) that has since ended. SaaS and Technology beat on Cybersecurity (best quarter ever). Adj. EBITDA was ahead on the revenue beat in addition to Circle Medical & WISP achieving slight profits (we were looking for a slight loss), even as the company accelerated digital ad campaigns to widen the patient funnel. WELL continues to advance its physical presence in the US, opening 18 clinics in Q1 to bring its total count to 23.

2023 guidance raised, more upside likely to come in our view. We see multiple opportunities for WELL to beat its increased outlook (First Take here) on better organic trends, in addition to more M&A, with management noting the current pipeline is among the most compelling it has ever seen. Canadian clinics should see upside through the recruitment of more doctors and as WELL absorbs more clinics. MyHealth and CRH Medical are poised to benefit from a y/y increase in more diagnostic services and anesthesia procedures, respectively. While our 2023 estimates have been raised (revenue $700M vs $677M previously, Adj. EBITDA $115m vs prior $114M), we expect Q2 to look similar to results in Q1. We expect revenue of $169.8M vs $169.5M in Q1 and Adj. EBITDA $27.0M vs. $26.7M. We model typical seasonality from Q1 to Q2 in Canadian clinics (less doctors visits vs winter months) and a lower level of Cybersecurity offset by qoq growth at CRH Medical, MyHealth, and at Circle Medical/WISP. While we expect strong growth at both Circle Medical and WISP, faster growth trends are anticipated in 2H. Adj. EBITDA margins in Q2 are forecast to be essentially flat qoq (15.9% vs 15.8%) and will be impacted by stepped up spending at WISP. Although we don’t include any M&A in our model, management noted opportunities in Canada (smaller clinic networks) and the US (bigger clinic networks), while it is exploring new approaches to acquiring providers (i.e., such as services that provide locums to hospitals and clinics). Leverage is manageable with net debt / shareholder Adj. EBITDA at 2.6x vs. 3.5x in Q1/22.

Exhibit 1 - Variance Table

Source: Company reports; Scotiabank GBM estimates; FactSet.

Historical price multiple calculations use FYE prices. All values in C$ unless otherwise indicated.
Source: FactSet; company reports; Scotiabank GBM estimates.